Prostate Cancer International is
for 2011 by Great NonProfits
Today’s news items deal with: The effect of dutasteride on the results of PCA3 tests How common is the TMPRSS2 fusion gene in men with prostate cancer in North America? Can prostate biopsy data predict laterality of prostate cancer with accuracy?
Filed under: Diagnosis, Risk, Uncategorized | Tagged: biopsy, dutasteride, ERG, laterality, PCA3, TMPRSS2 | 7 Comments »
There were probably over 100 posters related to prostate cancer presented at the ASCO meeting today (Sunday, May 31), so you will have to pardon us for not even attempting to report on all this vast variety of data. Rather, we have attempted to select out the papers that seem to offer the most interesting [...]
Filed under: Diagnosis, Drugs in development, Risk | Tagged: abiraterone acetate, PCA3 | Leave a Comment »
This morning’s reports deal with: New Japanese guidelines on prostate cancer screening PCA3 — “from bench to bedside” Impact of hormonal therapy on bone mineral density and risk for fractures The initial results of the RENEW trial
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ADT, BMD, bone mineral density, guidelines, Japan, PCA3, screening | Leave a Comment »
There has been hope in some quarters that the prostate cancer gene 3 or PCA3 test would provide data so helpful that we could dispense with the need for PSA testing at all. However, The “New” Prostate Cancer Infolink has long suspected — for a variety of reasons — that this would not be the [...]
Filed under: Diagnosis, Risk | Tagged: nomogram, PCA3, pre-biopsy, value | 7 Comments »
The PCA3 or prostate cancer gene 3 assay was approved some time ago for commercial use in Europe. It has not yet been approved by the U.S. Food and Drug Administration. What are the real differences between this test and the PSA test that we are all more accustomed too?
Filed under: Diagnosis, Management | Tagged: PCA3, prostate cancer gene 3 | 5 Comments »
A new review just published in BJU International provides a current expert perspective on the roles of PSA and the much newer PCA3 test in the work-up and diagnosis of a patient suspected of prostate cancer. The entire article is available on line and will be a useful resource for many support group leaders and [...]
Filed under: Diagnosis, Management, Treatment | Tagged: Diagnosis, PCA3, PSA, work-up | 2 Comments »
We have separately addressed a report from Australia on the potential of PSA “signatures” as prognostic indicators of prostate cancer progression. In other news today:
Filed under: Diagnosis, Management | Tagged: Diagnosis, endoglin, imaging, PCA3, staging | Leave a Comment »
In today’s reports, we include items on: The diagnosis and management of post-RP stress incontinence Another review of MRI in diagnosis of prostate cancer More on the potential of the PCA3 test in diagnosis of prostate cancer Results of early data on salvage LRP by a highly skilled team
Filed under: Diagnosis, Management, Treatment | Tagged: LRP, MRI, PCA3, salvage, stress incontinence | Leave a Comment »
In today’s update there is information about: Excess body mass and risk from prostate cancer death The potential role of the PCA3 test Focal treatment for localized disease using targeted photodynamic therapy
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: body mass, focal therapy, PCA3 | Leave a Comment »
According to an article by Whitman et al., so far only pre-published on line, the PCA3 urine test is capable of predicting risk for extracapsular extension in men with prostate cancer prior to radical prostatectomy.
Filed under: Diagnosis, Management, Treatment | Tagged: extracapsular extension, PCA3, risk | Leave a Comment »
And hot off today’s news: A report on salvage prostatectomy in low risk patients More on the potential of active sruveillance Two “new” proteins that may affect risk and progression And some follow-up on yesterday morning’s news report
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: active surveillance, monoamine oxidase-A, PCA3, prostatectomy, salvage, WAVE1 | Leave a Comment »
More news of a relatively theoretical nature today: The relevance of nuclear roundness variance in predicting risk of disease progression Incorporation of the PCA3 gene marker into the PCPT risk calculator Saving the neurovascular bundles has no impact on long-term continence
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: continence, Her-2/neu, neurovascular bundles, nuclear roundness, PCA3, progression | 1 Comment »
Anyone who has learned a reasonable amount about the diagnosis and management of prostate cancer has learned that the prostate specific antigen or PSA test is not a particularly good test for identifying or monitoring the status of men with active prostate cancer. It is simply better than anything else we have. Researchers have been [...]
Filed under: Diagnosis | Tagged: Diagnosis, PCA3, prostate cancer | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site